SecBot SecBot
SECBOTREPLAY Home › Report › TTRX

TTRX · $150M shelf + $50M ATM

Turn Therapeutics Inc. · S-3 filed Nov 9, 2026 at 08:05 ET

At the news

BEARISHIMPACT 6/10

S-3 filed Nov 9, 2026 at 08:05 ET

Turn Therapeutics filed a universal shelf registration statement on Form S-3 to offer up to $150M in securities, including a $50M at-the-market (ATM) equity program with TD Cowen. The company is a pre-revenue clinical-stage biotech with a net loss of $6.2M in Q3 2026 and only $10.4M in cash, making this a capital raise to fund operations and clinical trials into Q3 2027. The filing signals significant potential dilution for existing shareholders.

  • Shelf registration for up to $150M in securities, including a $50M ATM with TD Cowen.
  • Company reported a net loss of $6.2M in Q3 2026, wider than $1.9M loss in Q3 2025.
  • Cash and cash equivalents of $10.4M as of September 30, 2026, funding operations into Q3 2027.
  • Pre-revenue clinical-stage biotech with no approved products.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access